Neoadjuvant radiochemotherapy for locally advanced gastric cancer: A phase I-II study

Annals of Oncology

Volumn 14, Issue 1, 2003, Pages 110-115

  Roth, A D ^a   Allal, A S ^a   Brundler M A ^a   de Peyer, R ^a   Mermillod, B ^a   Morel, P ^a   Huber, O ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Gastric cancer; Neoadjuvant radiochemotherapy; Peritoneal relapse

Indexed keywords

ANTIEMETIC AGENT; CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; FATALITY; FATIGUE; FEBRILE NEUTROPENIA; HEMATOLOGICAL PARAMETERS; HISTOPATHOLOGY; HUMAN; KIDNEY FUNCTION; LEUKOPENIA; LIVER FUNCTION; MAXIMUM TOLERATED DOSE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; PERITONEUM CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RADIATION DOSE; SCORING SYSTEM; STOMACH ADENOCARCINOMA; SURGICAL RISK;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COMBINED MODALITY THERAPY; HUMANS; LEUCOVORIN; MAXIMUM TOLERATED DOSE; NEOADJUVANT THERAPY; NEOPLASM STAGING; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 0037246633     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg023     Document Type: Article

References (30)

1. Parkin DM. Epidemiology of cancer: global patterns and trends. Toxicol Lett 1998; 102-103: 227-234.
2. Hansson LE, Sparen P, Nyren O. Survival in stomach cancer is improving: results of a nationwide population-based Swedish study. Ann Surg 1999; 230: 162-169.
3. Hundahl SA, Menck HR, Mansour EG et al. The National Cancer Data Base report on gastric carcinoma. Cancer 1997; 80: 2333-2341.
4. Shimada K, Ajani JA. Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials. Cancer 1999; 86: 1657-1668.
5. Braga M, Zuliani W, Foppa L et al. Food intake and nutritional status after total gastrectomy: results of a nutritional follow-up. Br J Surg 1988; 75: 477-480.
6. Hebuterne X, Vaillon F, Peroux JL et al. Correction of malnutrition following gastrectomy with cyclic enteral nutrition. Dig Dis Sci 1999; 44: 1875-1882.
7. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinico-pathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1982; 8: 1-11.
8. Landry J, Tepper JE, Wood WC et al. Patterns of failure following curative resection of gastric carcinoma. Int J Radiat Oncol Biol Phys 1990; 19: 1357-1362.
9. Wisbeck WM, Becher EM, Russell AH. Adenocarcinoma of the stomach: autopsy observations with therapeutic implications for the radiation oncologist. Radiother Oncol 1986; 7: 13-18.
10. Dent DM, Werner ID, Novis B et al. Prospective randomized trial of combined oncological therapy for gastric carcinoma. Cancer 1979; 44: 385-391.
11. Hallissey MT, Dunn JA, Ward LC et al. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up. Lancet 1994; 343: 1309-1312.
12. Shchepotin IB, Evans SR, Chorny V et al. Intensive preoperative radiotherapy with local hyperthermia for the treatment of gastric carcinoma. Surg Oncol 1994; 3: 37-44.
13. Mahadevan A, Carey D. The role of radiotherapy in the surgical management of gastrointestinal cancer. Surg Oncol 1997; 6: 201-208.
14. Zhang ZX, Gu XZ, Yin WB et al. Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of adenocarcinoma of gastric cardia (AGC): report on 370 patients. Int J Radiat Oncol Biol Phys 1998; 42: 929-934.
15. Skoropad VY, Berdov BA, Mardynski YS et al. A prospective, randomized trial of pre-operative and intraoperative radiotherapy versus surgery alone in resectable gastric cancer. Eur J Surg Oncol 2000; 26: 773-779.
16. Bleiberg H, Jeziorsky K, Hendlisz A et al. Role of radiotherapy in cancers of the stomach. Bull Cancer 1997; 84: 913-916.
17. Macdonald JS, Smalley SR, Benedetti J et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
18. Wilke H, Preusser P, Fink U et al. Preoperative chemotherapy in locally advanced and nonresectable gastric cancer: a phase II study with etoposide, doxorubicin and cisplatin. J Clin Oncol 1989; 7: 1318-1326.
19. Rougier P, Mahjoubi M, Lasser P et al. Neoadjuvant chemotherapy in locally advanced gastric carcinoma-a phase II trial with combined continuous intravenous 5-fluorouracil and bolus cisplatinum. Eur J Cancer 1994; 30A: 1269-1275.
20. Ajani JA, Mayer RJ, Ota DM et al. Preoperative and postoperative combination chemotherapy for potentially resectable gastric carcinoma. J Natl Cancer Inst 1993; 85: 1839-1844.
21. Minsky BD. Carcinoma of the esophagus. Part 2: adjuvant therapy. Oncology 1999; 13: 1415-1427.
22. Lowy AM, Mansfield PF, Leach SD et al. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999; 229: 303-308.
23. Law S, Fok M, Chow S et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomized trial. J Thorac Cardiovasc Surg 1997; 114: 210-217.
24. Forastiere AA, Heitmiller RF, Lee DJ et al. Intensive chemoradiation followed by esophagectomy for squamous cell and adenocarcinoma of the esophagus. Cancer J Sci Am 1997; 3: 144-152.
25. Otsuji E, Yamaguchi T, Sawai K et al. Regional lymph node metastasis as a predictor of peritoneal carcinomatosis in patients with Borrmann type IV gastric carcinoma. Am J Gastroenterol 1999; 94: 434-437.
26. Roth AD, Maibach R, Martinelli G et al. Docetaxel (Taxotere)-cisplatin TC: an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 2000; 11: 301-306.
27. Roth AD, Maibach R, Fazio N et al. 5FU as protracted continuous IV infusion (5FUpiv) can be added to full dose Taxotere-cisplatin (TC) in advanced gastric carcinoma (AGC). Eur J Cancer 1999; 35 (Suppl. 4): S139-S130.
28. Bleiberg H. CPT-11 in gastrointestinal cancer. Eur J Cancer 1999; 35: 371-379.
29. Pozzo C, Szanto J, Peschel C et al. Irinotecan (Iri) in combination with CDDP (C) or with 5-FU and folinic acid (FU/FA) is active in patients (pts) with avanced gastric or gastroesophageal junction adenocarcinoma (AGC). Ann Oncol 2000; 11 (Suppl 4): 63-60.
30. Ajani JA. Current status of therapy for advanced gastric carcinoma. Oncology 1998; 12: 99-102.